Tekmira Secures $3M Loan, Discloses Trial Date for Alnylam Litigation | GenomeWeb

Tekmira Pharmaceuticals said this week that it has secured a $3 million loan, extending its cash runway into 2013.

Separately this week, Tekmira announced that a trial date of Oct. 30, 2012 has been set for its litigation with Alnylam Pharmaceuticals and AlCana Technologies.

According to the company, Silicon Valley Bank has agreed to provide a $3 million term loan, which can be drawn down at Tekmira's discretion at any time before Sept. 30, 2012. The loan matures on June 30, 2015, and carries a fixed annual interest rate of 8 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.